Q2 2025 Abbott Laboratories Earnings Call Transcript
Key Points
- Abbott Laboratories (ABT) reported high single-digit sales growth and over 100 basis points of margin expansion in both gross and operating margins.
- The company achieved double-digit earnings per share growth, exceeding consensus estimates.
- Sales in the Nutrition segment increased by 3.5%, driven by strong demand for Ensure and Glucerna brands.
- Medical Devices sales grew by 12%, with significant contributions from diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management.
- Abbott Laboratories (ABT) is making progress in its biosimilars portfolio, with 10 regulatory approval submissions completed and launches projected to begin in 2026.
- Diagnostics sales declined by 1.5% due to a decrease in COVID testing sales and volume-based procurement programs in China, representing a significant headwind.
- The company faces challenges in the China Core Lab market, impacting overall sales growth.
- There are ongoing headwinds from COVID testing sales drop-off and changes in US funding for HIV testing.
- Abbott Laboratories (ABT) is experiencing a $200 million impact from tariffs, which is affecting its financial performance.
- Foreign exchange remains a headwind on the bottom line, despite being neutral on the top line.
Good morning and thank you for standing by. Welcome to Abbott's second-quarter 2025 earnings conference call. (Operator Instructions)
This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission.
I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
